ADVISORY, March 2, 2010 (GLOBE NEWSWIRE) --
What:
Jens Bager, President and CEO of ALK-Abelló, will visit the NASDAQ MarketSite in New York City's Times Square and preside over the NASDAQ Closing Bell.
Where:
NASDAQ MarketSite -- 4 Times Square -- 43rd & Broadway -- Broadcast Studio
When:
Wednesday, March 3, 2010 at 3:45 p.m. to 4:00 p.m. ET
Contact:
NASDAQ MarketSite:
Jolene Libretto
(646) 441-5220
Jolene.Libretto@NASDAQOMX.com
Feed Information:
The Closing Bell is available from 3:50 p.m. to 4:05 p.m. on AMC-3/C-3 (ul 5985V; dl 3760H). The feed can also be found on Ascent fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.
Radio Feed:
An audio transmission of the Closing Bell is also available from 3:50 p.m. to 4:05 p.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Ascent fiber 1623 as well.
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page at:
http://www.facebook.com/pages/NASDAQ-OMX/108167527653
For news tweets, please visit our Twitter page at:
Webcast:
A live webcast of the NASDAQ Closing Bell will be available at:
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a high-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About ALK Abelló:
ALK is a global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. We are devoted to improving quality of life for people with allergies by developing pharmaceutical products that target the actual cause of allergy.
ALK is the world leader in allergy vaccination (immunotherapy) -- a unique treatment that induces a protective immune response which reduces and potentially halts the allergic reaction.
Allergy vaccination is traditionally administered as subcutaneous injections or sublingual droplets. Our aim is to extend the use of allergy vaccination by introducing convenient, tablet-based vaccines, thereby offering many more patients a causal allergy treatment.
Following this strategy, the world's first tablet-based vaccine against grass pollen allergy, GRAZAX®, was launched in Europe in 2006. In 2009, GRAZAX® was approved as a disease modifying allergy treatment and GRAZAX® is now the only registered tablet treatment against grass pollen allergy with documented sustained effect after completion of treatment.
ALK has more than 1,500 employees with subsidiaries, production facilities and distributors worldwide. The company is headquartered in Hørsholm, Denmark and listed on NASDAQ OMX Copenhagen A/S.
About NASDAQ OMX:
The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with approximately 3,700 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX First North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com. *Please follow NASDAQ OMX on Facebook (http://www.facebook.com/pages/NASDAQ-OMX/108167527653) and Twitter (http://www.twitter.com/nasdaqomx).
NDAQA